Home » Celgene Says FDA Panel Won’t Review Pomalidomide
Celgene Says FDA Panel Won’t Review Pomalidomide
Celgene said that a Food and Drug Administration panel will not review its multiple myeloma drug pomalidomide in November.
Businessweek
Businessweek
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May